{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T18:19:30Z","timestamp":1785521970410,"version":"3.56.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T00:00:00Z","timestamp":1782345600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T00:00:00Z","timestamp":1782345600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Ther"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s40744-026-00869-8","type":"journal-article","created":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T10:19:03Z","timestamp":1782382743000},"page":"1173-1190","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparison of Systemic Corticosteroid Therapy Practices Between Pediatric and Adult Rheumatologists: A Multicenter Survey Study"],"prefix":"10.1007","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8244-1226","authenticated-orcid":false,"given":"\u00d6vg\u00fc \u00d6zenli","family":"Ya\u011fc\u0131","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6901-9944","authenticated-orcid":false,"given":"\u00c7isem","family":"Y\u0131ld\u0131z","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4823-2076","authenticated-orcid":false,"given":"Deniz Gezgin","family":"Y\u0131ld\u0131r\u0131m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2260-4660","authenticated-orcid":false,"given":"Emre","family":"Bilgin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6530-9672","authenticated-orcid":false,"given":"Sevcan A.","family":"Bakkalo\u011flu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,25]]},"reference":[{"issue":"1","key":"869_CR1","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/1710-1492-9-30","volume":"9","author":"D Liu","year":"2013","unstructured":"Liu D, Ahmet A, Ward L, et al. A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. Allergy Asthma Clin Immunol. 2013;9(1):30. https:\/\/doi.org\/10.1186\/1710-1492-9-30.","journal-title":"Allergy Asthma Clin Immunol"},{"key":"869_CR2","volume-title":"Corticosteroids\u2014a paradigmatic drug class","author":"A Florescu","year":"2021","unstructured":"Florescu A, Mu\u015fetescu AE, Criveanu C, et al. Applications of corticosteroid therapy in inflammatory rheumatic diseases. In: Pereira C, editor., et al., Corticosteroids\u2014a paradigmatic drug class. London: IntechOpen; 2021."},{"issue":"5 Suppl 68","key":"869_CR3","first-page":"S148","volume":"29","author":"A Ravelli","year":"2011","unstructured":"Ravelli A, Lattanzi B, Consolaro A, Martini A. Glucocorticoids in paediatric rheumatology. Clin Exp Rheumatol. 2011;29(5 Suppl 68):S148\u201352.","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"869_CR4","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1136\/ard-2023-224270","volume":"83","author":"L van Ouwerkerk","year":"2024","unstructured":"van Ouwerkerk L, Verschueren P, Boers M, et al. Initial glucocorticoid bridging in rheumatoid arthritis: does it affect glucocorticoid use over time? Ann Rheum Dis. 2024;83(1):65\u201371. https:\/\/doi.org\/10.1136\/ard-2023-224270.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"869_CR5","doi-asserted-by":"publisher","first-page":"218","DOI":"10.4103\/0378-6323.33633","volume":"73","author":"CT Deshmukh","year":"2007","unstructured":"Deshmukh CT. Minimizing side effects of systemic corticosteroids in children. Indian J Dermatol Venereol Leprol. 2007;73(4):218\u201321. https:\/\/doi.org\/10.4103\/0378-6323.33633.","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"869_CR6","doi-asserted-by":"publisher","first-page":"152068","DOI":"10.1016\/j.semarthrit.2022.152068","volume":"56","author":"P Brogan","year":"2022","unstructured":"Brogan P, Naden R, Ardoin SP, et al. The pediatric glucocorticoid toxicity index. Semin Arthritis Rheum. 2022;56:152068. https:\/\/doi.org\/10.1016\/j.semarthrit.2022.152068.","journal-title":"Semin Arthritis Rheum"},{"issue":"12","key":"869_CR7","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1136\/ard.2007.072157","volume":"66","author":"JN Hoes","year":"2007","unstructured":"Hoes JN, Jacobs JWG, Boers M, et al. EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis. 2007;66(12):1560\u20137. https:\/\/doi.org\/10.1136\/ard.2007.072157.","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"869_CR8","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1136\/annrheumdis-2013-203249","volume":"72","author":"N Duru","year":"2013","unstructured":"Duru N, van der Goes MC, Jacobs JWG, et al. EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis. 2013;72(12):1905\u201313. https:\/\/doi.org\/10.1136\/annrheumdis-2013-203249.","journal-title":"Ann Rheum Dis"},{"key":"869_CR9","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1741-7015-2-7","volume":"2","author":"AM Huber","year":"2004","unstructured":"Huber AM, King J, McLaine P, Klassen T, Pothos M. A randomized, placebo-controlled trial of prednisone in early Henoch Sch\u00f6nlein Purpura [ISRCTN85109383]. BMC Med. 2004;2:7. https:\/\/doi.org\/10.1186\/1741-7015-2-7.","journal-title":"BMC Med"},{"issue":"9826","key":"869_CR10","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1016\/s0140-6736(11)61930-2","volume":"379","author":"T Kobayashi","year":"2012","unstructured":"Kobayashi T, Saji T, Otani T, et al. Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial. Lancet. 2012;379(9826):1613\u201320. https:\/\/doi.org\/10.1016\/s0140-6736(11)61930-2.","journal-title":"Lancet"},{"key":"869_CR11","doi-asserted-by":"publisher","first-page":"1128754","DOI":"10.3389\/fimmu.2023.1128754","volume":"14","author":"L Pan","year":"2023","unstructured":"Pan L, Liu J, Liu C, et al. Childhood-onset systemic lupus erythematosus: characteristics and the prospect of glucocorticoid pulse therapy. Front Immunol. 2023;14:1128754. https:\/\/doi.org\/10.3389\/fimmu.2023.1128754.","journal-title":"Front Immunol"},{"issue":"12","key":"869_CR12","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.1111\/cts.13649","volume":"16","author":"BI Wallace","year":"2023","unstructured":"Wallace BI, Tsai HJ, Lin P, et al. Prevalence and prescribing patterns of oral corticosteroids in the United States, Taiwan, and Denmark, 2009\u20132018. Clin Transl Sci. 2023;16(12):2565\u201376. https:\/\/doi.org\/10.1111\/cts.13649.","journal-title":"Clin Transl Sci"},{"issue":"3","key":"869_CR13","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/bf00541537","volume":"30","author":"SJ Szefler","year":"1986","unstructured":"Szefler SJ, Ebling WF, Georgitis JW, Jusko WJ. Methylprednisolone versus prednisolone pharmacokinetics in relation to dose in adults. Eur J Clin Pharmacol. 1986;30(3):323\u20139. https:\/\/doi.org\/10.1007\/bf00541537.","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"869_CR14","doi-asserted-by":"publisher","first-page":"167","DOI":"10.4103\/0019-5154.44786","volume":"53","author":"S Nayak","year":"2008","unstructured":"Nayak S, Acharjya B. Deflazacort versus other glucocorticoids: a comparison. Indian J Dermatol. 2008;53(4):167\u201370. https:\/\/doi.org\/10.4103\/0019-5154.44786.","journal-title":"Indian J Dermatol"},{"issue":"8","key":"869_CR15","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1002\/art.41773","volume":"73","author":"SA Chung","year":"2021","unstructured":"Chung SA, Langford CA, Maz M, et al. 2021 American College of Rheumatology\/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Arthritis Rheumatol. 2021;73(8):1366\u201383. https:\/\/doi.org\/10.1002\/art.41773.","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"869_CR16","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1136\/annrheumdis-2016-209247","volume":"76","author":"F Bellutti Enders","year":"2017","unstructured":"Bellutti Enders F, Bader-Meunier B, Baildam E, et al. Consensus-based recommendations for the management of juvenile dermatomyositis. Ann Rheum Dis. 2017;76(2):329\u201340. https:\/\/doi.org\/10.1136\/annrheumdis-2016-209247.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"869_CR17","doi-asserted-by":"publisher","first-page":"e8","DOI":"10.1093\/bjd\/ljae263","volume":"191","author":"R Murphy","year":"2024","unstructured":"Murphy R, Moots RJ, Brogan P, et al. British Association of Dermatologists and British Society for Rheumatology living guideline for managing people with Beh\u00e7ets 2024. Br J Dermatol. 2024;191(5):e8\u201325. https:\/\/doi.org\/10.1093\/bjd\/ljae263.","journal-title":"Br J Dermatol"},{"key":"869_CR18","doi-asserted-by":"publisher","unstructured":"Sammaritano LR, Askanase A, Bermas BL, et al. 2025 American College of Rheumatology (ACR) Guideline for the Treatment of Systemic Lupus Erythematosus (SLE). Arthritis Rheumatol. 2025. https:\/\/doi.org\/10.1002\/art.43452.","DOI":"10.1002\/art.43452"},{"issue":"12","key":"869_CR19","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1136\/ard-2024-225851","volume":"83","author":"B Fautrel","year":"2024","unstructured":"Fautrel B, Mitrovic S, De Matteis A, et al. EULAR\/PReS recommendations for the diagnosis and management of Still\u2019s disease, comprising systemic juvenile idiopathic arthritis and adult-onset Still\u2019s disease. Ann Rheum Dis. 2024;83(12):1614\u201327. https:\/\/doi.org\/10.1136\/ard-2024-225851.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"869_CR20","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1002\/art.41774","volume":"73","author":"M Maz","year":"2021","unstructured":"Maz M, Chung SA, Abril A, et al. 2021 American College of Rheumatology\/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis. Arthritis Rheumatol. 2021;73(8):1349\u201365. https:\/\/doi.org\/10.1002\/art.41774.","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"869_CR21","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1136\/annrheumdis-2019-215672","volume":"79","author":"B Hellmich","year":"2020","unstructured":"Hellmich B, Agueda A, Monti S, et al. 2018 Update of the EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis. 2020;79(1):19\u201330. https:\/\/doi.org\/10.1136\/annrheumdis-2019-215672.","journal-title":"Ann Rheum Dis"},{"key":"869_CR22","doi-asserted-by":"publisher","unstructured":"Abdwani R. Pediatric rheumatology. In: Almoallim H, Cheikh M, editors. Skills in rheumatology. Singapore: Springer. https:\/\/doi.org\/10.1007\/978-981-15-8323-0_24.","DOI":"10.1007\/978-981-15-8323-0_24"},{"issue":"2","key":"869_CR23","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/s41584-023-01065-6","volume":"20","author":"P Ruscitti","year":"2024","unstructured":"Ruscitti P, Cantarini L, Nigrovic PA, McGonagle D, Giacomelli R. Recent advances and evolving concepts in Still\u2019s disease. Nat Rev Rheumatol. 2024;20(2):116\u201332. https:\/\/doi.org\/10.1038\/s41584-023-01065-6.","journal-title":"Nat Rev Rheumatol"},{"issue":"2","key":"869_CR24","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s12016-020-08831-4","volume":"62","author":"M Zhao","year":"2022","unstructured":"Zhao M, Wu J, Wu H, Sawalha AH, Lu Q. Clinical treatment options in scleroderma: recommendations and comprehensive review. Clin Rev Allergy Immunol. 2022;62(2):273\u201391. https:\/\/doi.org\/10.1007\/s12016-020-08831-4.","journal-title":"Clin Rev Allergy Immunol"},{"issue":"1","key":"869_CR25","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1111\/1756-185x.14260","volume":"25","author":"A Furusawa","year":"2022","unstructured":"Furusawa A, Wakiguchi H, Okazaki F, et al. Successful treatment of children with juvenile systemic sclerosis using mycophenolate mofetil after methylprednisolone pulse therapy: a 3-year follow-up. Int J Rheum Dis. 2022;25(1):95\u20136. https:\/\/doi.org\/10.1111\/1756-185x.14260.","journal-title":"Int J Rheum Dis"},{"issue":"8","key":"869_CR26","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1002\/acr.21687","volume":"64","author":"SC Li","year":"2012","unstructured":"Li SC, Torok KS, Pope E, et al. Development of consensus treatment plans for juvenile localized scleroderma: a roadmap toward comparative effectiveness studies in juvenile localized scleroderma. Arthritis Care Res (Hoboken). 2012;64(8):1175\u201385. https:\/\/doi.org\/10.1002\/acr.21687.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"2","key":"869_CR27","doi-asserted-by":"publisher","first-page":"241","DOI":"10.3899\/jrheum.180582","volume":"47","author":"P Moinzadeh","year":"2020","unstructured":"Moinzadeh P, Kuhr K, Siegert E, et al. Scleroderma renal crisis: risk factors for an increasingly rare organ complication. J Rheumatol. 2020;47(2):241\u20138. https:\/\/doi.org\/10.3899\/jrheum.180582.","journal-title":"J Rheumatol"},{"key":"869_CR28","doi-asserted-by":"publisher","first-page":"152355","DOI":"10.1016\/j.semarthrit.2023.152355","volume":"65","author":"U Rathore","year":"2024","unstructured":"Rathore U, Chandwar K, Singh K, Misra DP. Pediatric-onset Takayasu arteritis is associated with greater risk of mortality than adult-onset Takayasu arteritis\u2013a systematic review with meta-analysis of observational cohort studies. Semin Arthritis Rheum. 2024;65:152355. https:\/\/doi.org\/10.1016\/j.semarthrit.2023.152355.","journal-title":"Semin Arthritis Rheum"},{"issue":"9","key":"869_CR29","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/S0248-8663(03)00069-9","volume":"24","author":"P S\u00e8ve","year":"2003","unstructured":"S\u00e8ve P, Bui-Xuan C, Charhon A, Broussolle C. La maladie de Kawasaki de l\u2019adulte. Rev Med Interne. 2003;24(9):577\u201384. https:\/\/doi.org\/10.1016\/S0248-8663(03)00069-9.","journal-title":"Rev Med Interne"},{"issue":"23","key":"869_CR30","doi-asserted-by":"publisher","first-page":"e481","DOI":"10.1161\/CIR.0000000000001295","volume":"150","author":"P-N Jone","year":"2024","unstructured":"Jone P-N, Tremoulet A, Choueiter N, et al. Update on diagnosis and management of Kawasaki disease: a scientific statement from the American Heart Association. Circulation. 2024;150(23):e481\u2013500. https:\/\/doi.org\/10.1161\/CIR.0000000000001295.","journal-title":"Circulation"},{"issue":"4","key":"869_CR31","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1002\/acr.24838","volume":"74","author":"M Gorelik","year":"2022","unstructured":"Gorelik M, Chung SA, Ardalan K, et al. 2021 American College of Rheumatology\/Vasculitis Foundation Guideline for the Management of Kawasaki Disease. Arthritis Care Res (Hoboken). 2022;74(4):538\u201348. https:\/\/doi.org\/10.1002\/acr.24838.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"4","key":"869_CR32","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1093\/rheumatology\/key344","volume":"58","author":"N de Graeff","year":"2018","unstructured":"de Graeff N, Groot N, Ozen S, et al. European consensus-based recommendations for the diagnosis and treatment of Kawasaki disease \u2013 the SHARE initiative. Rheumatology. 2018;58(4):672\u201382. https:\/\/doi.org\/10.1093\/rheumatology\/key344.","journal-title":"Rheumatology"},{"issue":"7","key":"869_CR33","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1136\/annrheumdis-2022-222338","volume":"81","author":"L van Ouwerkerk","year":"2022","unstructured":"van Ouwerkerk L, Palmowski A, Nevins IS, et al. Systematic literature review of observational cohorts and clinical trials into the success rate of glucocorticoid discontinuation after their use as bridging therapy in patients with rheumatoid arthritis. Ann Rheum Dis. 2022;81(7):937\u201343. https:\/\/doi.org\/10.1136\/annrheumdis-2022-222338.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"869_CR34","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.reumae.2018.06.004","volume":"16","author":"R Sanmart\u00ed","year":"2020","unstructured":"Sanmart\u00ed R, Tornero J, Narv\u00e1ez J, et al. Efficacy and safety of glucocorticoids in rheumatoid arthritis: systematic literature review. Reumatol Clin (Engl Ed). 2020;16(3):222\u20138. https:\/\/doi.org\/10.1016\/j.reumae.2018.06.004.","journal-title":"Reumatol Clin (Engl Ed)"},{"issue":"6","key":"869_CR35","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1002\/acr.23870","volume":"71","author":"S Ringold","year":"2019","unstructured":"Ringold S, Angeles-Han ST, Beukelman T, et al. 2019 American College of Rheumatology\/Arthritis Foundation Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Non-Systemic Polyarthritis, Sacroiliitis, and Enthesitis. Arthritis Care Res (Hoboken). 2019;71(6):717\u201334. https:\/\/doi.org\/10.1002\/acr.23870.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"1","key":"869_CR36","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s00296-018-4168-0","volume":"39","author":"ED Batu","year":"2019","unstructured":"Batu ED. Glucocorticoid treatment in juvenile idiopathic arthritis. Rheumatol Int. 2019;39(1):13\u201327. https:\/\/doi.org\/10.1007\/s00296-018-4168-0.","journal-title":"Rheumatol Int"},{"issue":"1","key":"869_CR37","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/ard-2022-223356","volume":"82","author":"JS Smolen","year":"2023","unstructured":"Smolen JS, Landew\u00e9 RBM, Bergstra SA, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3\u201318. https:\/\/doi.org\/10.1136\/ard-2022-223356.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"869_CR38","doi-asserted-by":"publisher","first-page":"rkad102","DOI":"10.1093\/rap\/rkad102","volume":"7","author":"JA Prior","year":"2023","unstructured":"Prior JA, Roddy E, Solis-Trapala I, et al. How do clinicians prescribe bridging glucocorticoids in people starting or escalating disease-modifying anti-rheumatic drugs for rheumatoid arthritis: a service evaluation survey. Rheumatol Adv Pract. 2023;7(3):rkad102. https:\/\/doi.org\/10.1093\/rap\/rkad102.","journal-title":"Rheumatol Adv Pract"},{"key":"869_CR39","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.bcp.2019.04.009","volume":"165","author":"I Petta","year":"2019","unstructured":"Petta I, Peene I, Elewaut D, Vereecke L, De Bosscher K. Risks and benefits of corticosteroids in arthritic diseases in the clinic. Biochem Pharmacol. 2019;165:112\u201325. https:\/\/doi.org\/10.1016\/j.bcp.2019.04.009.","journal-title":"Biochem Pharmacol"},{"key":"869_CR40","doi-asserted-by":"publisher","first-page":"152349","DOI":"10.1016\/j.semarthrit.2023.152349","volume":"64","author":"A Palmowski","year":"2024","unstructured":"Palmowski A, Pankow A, Terziyska K, et al. Continuing versus tapering low-dose glucocorticoids in patients with rheumatoid arthritis and systemic lupus erythematosus in states of low disease activity or remission: a systematic review and meta-analysis of randomised trials. Semin Arthritis Rheum. 2024;64:152349. https:\/\/doi.org\/10.1016\/j.semarthrit.2023.152349.","journal-title":"Semin Arthritis Rheum"},{"issue":"4","key":"869_CR41","doi-asserted-by":"publisher","first-page":"350","DOI":"10.4103\/ijem.ijem_410_23","volume":"28","author":"G Priya","year":"2024","unstructured":"Priya G, Laway BA, Ayyagari M, et al. The glucocorticoid taper: a primer for the clinicians. Indian J Endocrinol Metab. 2024;28(4):350\u201362. https:\/\/doi.org\/10.4103\/ijem.ijem_410_23.","journal-title":"Indian J Endocrinol Metab"},{"issue":"10","key":"869_CR42","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1007\/s12098-008-0210-7","volume":"75","author":"A Sinha","year":"2008","unstructured":"Sinha A, Bagga A. Pulse steroid therapy. Indian J Pediatr. 2008;75(10):1057\u201366. https:\/\/doi.org\/10.1007\/s12098-008-0210-7.","journal-title":"Indian J Pediatr"},{"key":"869_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychores.2023.111179","volume":"167","author":"K Ogyu","year":"2023","unstructured":"Ogyu K, Mashima Y, Nishi A, et al. Intravenous pulse methylprednisolone and corticosteroid-induced psychiatric disorders: a retrospective study. J Psychosom Res. 2023;167:111179. https:\/\/doi.org\/10.1016\/j.jpsychores.2023.111179.","journal-title":"J Psychosom Res"},{"issue":"6","key":"869_CR44","doi-asserted-by":"publisher","first-page":"e1442","DOI":"10.1210\/clinem\/dgad701","volume":"109","author":"A-SCAM Koning","year":"2023","unstructured":"Koning A-SCAM, van der Meulen M, Schaap D, et al. Neuropsychiatric adverse effects of synthetic glucocorticoids: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2023;109(6):e1442\u201351. https:\/\/doi.org\/10.1210\/clinem\/dgad701.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"869_CR45","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.rdc.2015.08.004","volume":"42","author":"J Youssef","year":"2016","unstructured":"Youssef J, Novosad SA, Winthrop KL. Infection risk and safety of corticosteroid use. Rheum Dis Clin N Am. 2016;42(1):157\u201376. https:\/\/doi.org\/10.1016\/j.rdc.2015.08.004. (ix-x).","journal-title":"Rheum Dis Clin N Am"},{"key":"869_CR46","unstructured":"European Centre for Disease Prevention and Control. Hepatitis\u00a0B\u2014Annual Epidemiological Report for 2022. Internet. Stockholm: EDCD."},{"key":"869_CR47","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/1546-0096-8-17","volume":"8","author":"EM Eisenstein","year":"2010","unstructured":"Eisenstein EM, Wolf DG. Cytomegalovirus infection in pediatric rheumatic diseases: a review. Pediatr Rheumatol Online J. 2010;8:17. https:\/\/doi.org\/10.1186\/1546-0096-8-17.","journal-title":"Pediatr Rheumatol Online J"},{"issue":"4","key":"869_CR48","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1111\/j.1442-200X.2008.02629.x","volume":"50","author":"Y Nerome","year":"2008","unstructured":"Nerome Y, Imanaka H, Nonaka Y, Takei S, Kawano Y. Frequent methylprednisone pulse therapy is a risk factor for steroid cataracts in children. Pediatr Int. 2008;50(4):541\u20135. https:\/\/doi.org\/10.1111\/j.1442-200X.2008.02629.x.","journal-title":"Pediatr Int"},{"issue":"1","key":"869_CR49","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1136\/annrheumdis-2019-215882","volume":"79","author":"V Furer","year":"2020","unstructured":"Furer V, Rondaan C, Heijstek MW, et al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2020;79(1):39\u201352. https:\/\/doi.org\/10.1136\/annrheumdis-2019-215882.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"869_CR50","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1093\/cid\/ciae613","volume":"80","author":"X Wang","year":"2025","unstructured":"Wang X, Patel C, Giles ML, et al. Glucocorticoid dosing and implications for vaccination: evolution of global definitions. Clin Infect Dis. 2025;80(5):998\u20131004. https:\/\/doi.org\/10.1093\/cid\/ciae613.","journal-title":"Clin Infect Dis"}],"container-title":["Rheumatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-026-00869-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40744-026-00869-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-026-00869-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T17:10:00Z","timestamp":1785517800000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40744-026-00869-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,25]]},"references-count":50,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["869"],"URL":"https:\/\/doi.org\/10.1007\/s40744-026-00869-8","relation":{},"ISSN":["2198-6576","2198-6584"],"issn-type":[{"value":"2198-6576","type":"print"},{"value":"2198-6584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,25]]},"assertion":[{"value":"6 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"\u00d6vg\u00fc \u00d6zenli Ya\u011fc\u0131 has nothing to disclose. \u00c7isem Y\u0131ld\u0131z has nothing to disclose. Deniz Gezgin Y\u0131ld\u0131r\u0131m has nothing to disclose. Emre Bilgin: has nothing to disclose. Emre Bilgin is an Editorial Board member of\n                      Rheumatology and Therapy\n                      . Emre Bilgin was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.Sevcan Azime Bakkalo\u011flu: has nothing to disclose.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The present study was conducted in accordance with the Declaration of Helsinki and approved by the local ethics committee of the Gazi University Medical Faculty (Decision number E-77082166-604.01-1287324\/2025-1247 dated 14.07.2025). All participants consented to participate in the survey study.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}